For 25 years, RaySearch Laboratories has been creating value by advancing cancer treatment through software innovation. We have the ambition to keep you updated about our performance and other factors contributing to your assessment of RaySearch as an investment.
INVESTOR RELATIONS

LATEST PRESENTATION
Q2 REPORT 2025
RaySearch Laboratories published its interim report for the second quarter of 2025 on August 8. A webcast presentation was held the same day.
Net sales & Operating profit
Annual Report 2024
IR contact

- Carolina Haglund Strömlid
- Head of Investor Relations
- ir@raysearchlabs.com
- +46 (0)70 880 71 73